SHERMAN JEFFREY W 4
4 · Xeris Biopharma Holdings, Inc. · Filed Aug 29, 2025
Insider Transaction Report
Form 4
SHERMAN JEFFREY W
Director
Transactions
- Sale
Common Stock
2025-08-28$7.92/sh−42,232$334,515→ 219,188 total - Exercise/Conversion
Common Stock
2025-08-28$6.66/sh+47,040$313,286→ 261,420 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-08-28−47,040→ 0 totalExercise: $6.66Exp: 2026-10-01→ Common Stock (47,040 underlying)
Holdings
- 5,400(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.